蓝纳成 builds a class‑1 integrated diagnostic-and-therapeutic oncology radiopharmaceutical R&D platform focused on precision treatments for cancer patients. The company operates a large comprehensive laboratory that integrates targeted drug synthesis, radiolabeling, preclinical cell and animal experiments, and molecular imaging. It owns multiple proprietary global IP assets described as "albumin-binding—Evans blue modified" targeted radiopharmaceuticals. 蓝纳成 has developed a relatively complete radionuclide diagnosis-and-therapy pipeline covering small molecules, peptides, and antibodies. Indications in its pipeline include prostate cancer, solid tumors, glioma, and neuroendocrine tumors. The company recently completed a RMB 300 million B+ financing at a reported pre-money valuation of RMB 1.95 billion.

Total raised

$41M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2024